OBJECTIVES: The objective of this study is to assess the health care costs associated with Teriflunomide treatment for patients diagnosed with relapsing remitting multiple sclerosis (RRMS) in 2012 in the US METHODS: A large US administrative retrospective claims database was used to identify patients diagnosed with RRMS and were prescribed Terfilunomide between September 2012 to December 2012 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan for a year. Descriptive statistics and chi-square tests were performed on the data. RESULTS: There were a total of 157 patients that met the study inclusion criteria. Patients on average were charged $3816.90 ± 1702.83 for their treatment with Teriflunomide during the study period. However, the allowed amount by the health plan was $3635.28 ± 1314.56 and the actual paid amount was $3552.75 ± 1320.71. On average, patient’s deductible was $12.81 ± 96.33 and patient co-payment was $84.66 ± 184.95. For patients whose prescription was on their health plans formulary were charged less but paid more on the deductible and co-payment compared to patients who were not (charged amount $3646 vs $3829; deductible $14 vs $11; co-payment $122 vs $63) on the formulary. Even though most of the patients were females, but they had overall lower costs compared to males (amount allowed $3475 vs $4057; paid amount $3391 vs $3980). Patients who received treatment in the southern region of the USA had a higher costs compared to east, Midwest, and west regions (paid amount $3720 vs $3592 vs $3673 vs $2613).  CONCLUSIONS: The cost of Teriflunomide treatment for RRMS patients is higher and costing the health plan around $3552 per month. The cost of the drug treatment was higher in southern of the USA and males were paying more in general.